Cooperative Agreement Summary

The National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), awarded the University of Arizona $310,412 through a Cooperative Agreement effective June 24, 2026, through May 31, 2032. This funding establishes the University of Arizona Cancer Center (UACC) as a Lead Academic Participating Site (LAPS) within the NCI's National Clinical Trials Network (NCTN). The UACC will develop, lead, and participate in scientifically relevant NCTN clinical trials while supporting robust patient accrual, timely data reporting, and internal monitoring across Arizona-based trial sites. The center will leverage its infrastructure to coordinate clinical trial activities across satellite sites throughout Arizona as part of the Arizona Clinical Trials Network.

The award supports the UACC's core mission to strengthen clinical research infrastructure, protocol development, investigator leadership, and junior faculty mentorship in cancer treatment research. Deliverables include enhanced clinical trial enrollment capabilities, implementation of a clinical trials oncology navigation program to improve patient education and enrollment of diverse populations reflective of Arizona's demographics, and provision of scientific leadership in state-of-the-art adult cancer treatment trials. As Arizona's only NCI-designated Comprehensive Cancer Center, the UACC will continue its established track record of NCTN participation while training the next generation of clinical investigators through this cooperative funding mechanism.